Apellis Pharmaceuticals Inc

Biogen closed its $5.3 billion acquisition of Apellis, ending APLS trading on Nasdaq. Shareholders got $41 per share plus a CVR linked to Syfovre sales milestones.

Biogen has completed its $5.6 billion acquisition of Apellis Pharmaceuticals, delisting APLS from Nasdaq. Shareholders received $41 per share plus a contingent value right linked to Syfovre sales targets.

Apellis Pharmaceuticals has been delisted from Nasdaq following Biogen's completed acquisition. Shareholders get $41 per share plus a contingent value right worth up to $4 if Syfovre meets sales goals.

Biogen completed its $41/share cash acquisition of Apellis, delisting the stock from Nasdaq. Shareholders also received a contingent value right that could pay up to $4 if Syfovre sales hit targets.

Biogen has completed its acquisition of Apellis Pharmaceuticals, delisting APLS shares. Biogen gains Syfovre and Empaveli, plus a kidney disease pipeline, with a CVR tied to Syfovre sales.

Biogen closed its $5.3 billion acquisition of Apellis Pharmaceuticals, making Apellis a wholly owned subsidiary and ending its Nasdaq listing.

Biogen has entered a definitive agreement to acquire Apellis Pharmaceuticals for approximately $5.6 billion. The deal includes a $41 per share cash offer plus contingent value rights.

Biogen has entered an agreement to acquire Apellis Pharmaceuticals for approximately $5.6 billion in cash. The deal provides Apellis shareholders $41 per share upfront, with potential additional payments based on sales performance of the eye drug Syfovre.